Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment

被引:8
|
作者
Rosic, Tea [1 ,2 ]
Naji, Leen [2 ,3 ]
Sanger, Nitika [4 ]
Marsh, David C. [5 ,6 ,7 ,8 ]
Worster, Andrew [2 ,9 ]
Thabane, Lehana [2 ]
Samaan, Zainab [1 ,2 ]
机构
[1] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada
[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[3] McMaster Univ, Dept Family Med, Hamilton, ON, Canada
[4] McMaster Univ, Med Sci Grad Program, Hamilton, ON, Canada
[5] Northern Ontario Sch Med, Sudbury, ON, Canada
[6] Canadian Addict Treatment Ctr, Markham, ON, Canada
[7] ICES North, Sudbury, ON, Canada
[8] Hlth Sci North Res Inst, Sudbury, ON, Canada
[9] McMaster Univ, Dept Med, Hamilton, ON, Canada
基金
加拿大健康研究院;
关键词
buprenorphine; COVID-19; methadone; opioid use disorder; SARS-COV-2; USE DISORDER;
D O I
10.1097/ADM.0000000000000939
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objectives The opioid use disorder (OUD) crisis in North America has become "an epidemic within a pandemic" in the context of the COVID-19 virus. We aimed to explore the association between the COVID-19 pandemic and changes in opioid use patterns among patients receiving treatment for OUD. Methods We used prospectively collected data from 456 patients attending 31 opioid agonist clinics across Ontario, Canada. All included participants underwent routine urine drug screens (UDSs) both before and after the onset of the COVID-19 pandemic. A paired sample t-test was used to compare the proportion of opioid-positive UDSs collected pre- and post-pandemic, and linear regression analysis was used to explore factors associated with this change. Results Participants had a mean age of 39.9 years (standard deviation = 10.9), 52%were male, and 81%were receivingmethadone treatment. The percentage of opioid-positive UDSs increased significantly during the pandemic, on average by 10.6% (95% confidence interval [CI] 8.17, 12.95, P < 0.001). Continued opioid use before the pandemic was associated with 9.43% increase, on average, in the percentage of opioid-positive UDSs during the pandemic (95% CI 3.79, 15.07). Self-reported past-month cocaine (adjusted betacoefficient 6.83, 95% CI 0.92, 12.73) and amphetamine (adjusted beta-coefficient 13.13, 95% CI 5.15, 21.1) use at study entry were also associated with increases in opioid-positive UDSs. Conclusions Increased opioid use is one measure of the negative impact the COVID-19 pandemic has had on individuals with OUD, an already marginalized population. Understanding factors associated with worse outcomes is essential to ensuring that treatment programs appropriately adapt to better serve this population during the pandemic.
引用
收藏
页码:E257 / E264
页数:8
相关论文
共 50 条
  • [1] Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
    Morin, Kristen A.
    Acharya, Shreedhar
    Eibl, Joseph K.
    Marsh, David C.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 90
  • [2] Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study
    Scott, Gemma
    Turner, Sophie
    Lowry, Natalie
    Hodge, Annette
    Ashraf, Waniya
    McClean, Katie
    Kelleher, Mike
    Mitcheson, Luke
    Marsden, John
    BMJ OPEN, 2023, 13 (03):
  • [3] Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic
    Lee, Kenneth
    Zhao, Yue
    Merali, Tazmin
    Fraser, Christopher
    Kozicky, Jan-Marie
    Mormont, Marie-Christine
    Conway, Brian
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (06) : E374 - E381
  • [4] Opioid Policy Changes During the COVID-19 Pandemic - and Beyond
    Davis, Corey S.
    Samuels, Elizabeth A.
    JOURNAL OF ADDICTION MEDICINE, 2020, 14 (04) : E4 - E5
  • [5] High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
    Galvez, Samy J.
    Altice, Frederick L.
    Meteliuk, Anna
    Ivasiy, Roman
    Machavariani, Eteri
    Farnum, Scott O.
    Fomenko, Tetiana
    Islam, Zahedul
    Madden, Lynn M.
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [6] Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
    Meteliuk, Anna
    de Leon, Samy J. Galvez
    Madden, Lynn M.
    Pykalo, Iryna
    Fomenko, Tatiana
    Filippovych, Myroslava
    Farnum, Scott O.
    Dvoryak, Sergii
    Islam, Zahedul M.
    Altice, Frederick L.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 121
  • [7] Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review
    Krawczyk, Noa
    Fawole, Adetayo
    Yang, Jenny
    Tofighi, Babak
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)
  • [8] Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky
    Lei, Feitong
    Lofwall, Michelle R.
    Freeman, Patricia R.
    Slade, Emily
    Vickers-Smith, Rachel
    Slavova, Svetla
    JOURNAL OF RURAL HEALTH, 2023, 39 (01): : 186 - 196
  • [9] Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic
    Perry, Allison
    Wheeler-Martin, Katherine
    Hasin, Deborah S.
    Terlizzi, Kelly
    Mannes, Zachary L.
    Jent, Victoria
    Townsend, Tarlise N.
    Ii, John R. Pamplin
    Crystal, Stephen
    Martins, Silvia S.
    Cerd, Magdalena
    Krawczyk, Noa
    DRUG AND ALCOHOL DEPENDENCE, 2023, 253
  • [10] A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19
    Lockard, Rachel
    Priest, Kelsey C.
    Gregg, Jessica
    Buchheit, Bradley M.
    SUBSTANCE ABUSE, 2022, 43 (01) : 1150 - 1157